检索结果-南通市图书馆

Towards the full realization of the RIBLL2 beam line at the HIRFL-CSR complex

在线全文

学校读者我要写书评

暂无评论

Science Bulletin 2018年第2期63卷 78-80页

作者： Bao-hua Sun jian-Wei Zhao xue-Heng Zhang li-Na sheng Zhi-Yu Sun Isao Tanihata Satoru Terashima Yong Zheng li-hua Zhu li-Min Duan liu-Chun He Rong-jiang Hu Guang-Shuai li Wen-jian lin Wei-Ping lin Chuan-Ye liu zhong liu Chen-Gui Lu Xin-Wen Ma li-Jun Mao Yi Tian feng Wang Meng Wang Shi-Tao Wang Jia-Wen Xia Xiao-Dong xu Hu-Shan xu Zhi-guo xu jian-Cheng Yang Da-Yu Yin You-Jin Yuan Wen-Long Zhan Yu-Hu Zhang Xiao-Hong Zhou School of Physics and Nuclear Energy Engineering Beihang University Beijing 100191 China International Research Center for Nuclei and Particles in the Cosmos Beijing 100191 China Institute of Modern Physics Chinese Academy of Sciences Lanzhou 730000 China

More than 99%of the mass in the visible universe—the material that makes up ourselves,our planet,stars—is in the atomic *** the matter has existed for billions of years,only over the past few decades have we had the tools and the knowledge necessary to get a basic understanding of the structure and dynamic of *** physicists around the world have made tremendous strides by initiating a broad range of key

关键词： HIRFL-CSR 横梁建筑群排队原子核物理学家试验性世界

lijiang 2.4-meter Telescope and its instruments

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2019年第10期19卷 95-108页

作者： Chuan-Jun Wang Jin-Ming Bai Yu-feng Fan Ji-Rong Mao liang chang Yu-Xin Xin Ju-Jia Zhang Bao-li Lun jian-guo Wang Xi-liang Zhang Mei Ying Kai-Xing Lu Xiao-li Wang Kai-Fan Ji Ding-Rong Xiong Xiao-Guang Yu xu Ding Kai Ye li-feng Xing Wei-Min Yi liang xu xiang-Ming Zheng Yuan-Jie feng Shou-sheng He xue-li Wang zhong liu Dong Chen Jun xu Song-Nian Qin Rui-Long Zhang Hui-Song Tan Zhi li Ke Lou jian li Wei-Wei liu Yunnan Observatories Chinese Academy of SciencesKunming 650216China Key Laboratory for the Structure and Evolution of Celestial Objects Chinese Academy of Sciences Kunming 650216 China Center for Astronomical Mega-Science Chinese Academy of Sciences Beijing 100101 China University of Chinese Academy of Sciences Beijing 100049 China Astrophysics Center of Guangzhou University Guangzhou 510006China

The lijiang 2.4-meter Telescope(LJT), the largest common-purpose optical telescope in China,has been available to the worldwide astronomical community since 2008. It is located at the Gaomeigu site,lijiang Observatory(LJO), in the southwest of China. The site has very good observational *** its 10-year operation, several instruments have been equipped on the LJT. Astronomers can perform both photometric and spectral observations. The main scientific goals of LJT include recording photometric and spectral evolution of supernovae, reverberation mapping of active galactic nuclei, investigating the physical properties of binary stars and near-earth objects(comets and asteroids), and identification of exoplanets and all kinds of transients. Until now, the masses of 41 high accretion rate black holes have been measured, and more than 168 supernovae have been identified by the LJT. More than 190 papers related to the LJT have been published. In this paper, the general observation conditions of the Gaomeigu site is introduced at first. Then, the structure of the LJT is described in detail, including the optical, mechanical, motion and control system. The specification of all the instruments and some detailed parameters of the YFOSC is also presented. Finally, some important scientific results and future expectations are summarized.

关键词： telescopes lijiang 2.4-m Telescope-instrumentation photometers-instrumentation spectrographs

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST)

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2012年第9期12卷 1197-1242页

作者： xiang-Qun Cui Yong-Heng Zhao Yao-Quan Chu guo-Ping li Qi li li-Ping Zhang Hong-Jun Su Zheng-Qiu Yao Ya-Nan Wang Xiao-Zheng Xing Xin-Nan li Yong-Tian Zhu Gang Wang Bo-zhong Gu A-li Luo Xin-Qi xu Zhen-Chao Zhang Gen-Rong liu Hao-Tong Zhang De-hua Yang Shu-Yun Cao Hai-Yuan Chen jian-Jun Chen Kun-Xin Chen Ying Chen Jia-Ru Chu Lei feng xue-Fei Gong Yong-Hui Hou Hong-Zhuan Hu Ning-sheng Hu zhong-Wen Hu Lei Jia Fang-hua jiang xiang jiang Zi-Bo jiang Ge Jin Ai-hua li Yan li Ye-Ping li Guan-Qunliu Zhi-Gang liu Huo-Ming Shi Zheng-Hong Tang Qing-sheng Tao xiang-Yan Yuan Chao Zhai Jing Zhang Yan-Xia Zhang Yong Zhang Ming Zhao Fang Zhou guo-hua Zhou Jie Zhu Si-Cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China yzhao @ *** Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Tecfinologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

The Large Sky Area Multi-Object Fiber Spectroscopic Telescope (LAMOST, also called the guo Shou Jing Telescope) is a special reflecting Schmidt telescope. LAMOST’s special design allows both a large aperture (effective aperture of 3.6 m–4.9 m) and a wide field of view (FOV) (5°). It has an innovative active reflecting Schmidt configuration which continuously changes the mirror’s surface that adjusts during the observation process and combines thin deformable mirror active optics with segmented active optics. Its primary mirror (6.67m×6.05 m) and active Schmidt mirror (5.74m×4.40 m) are both segmented, and composed of 37 and 24 hexagonal sub-mirrors respectively. By using a parallel controllable fiber positioning technique, the focal surface of 1.75 m in diameter can accommodate 4000 optical fibers. Also, LAMOST has 16 spectrographs with 32 CCD cameras. LAMOST will be the telescope with the highest rate of spectral acquisition. As a national large scientific project, the LAMOST project was formally proposed in 1996, and approved by the Chinese government in 1997. The construction started in 2001, was completed in 2008 and passed the official acceptance in June 2009. The LAMOST pilot survey was started in October 2011 and the spectroscopic survey will launch in September 2012. Up to now, LAMOST has released more than 480 000 spectra of objects. LAMOST will make an important contribution to the study of the large-scale structure of the Universe, structure and evolution of the Galaxy, and cross-identification of multiwaveband properties in celestial objects.

关键词： techniques: wide field telescope - active optics - multi fiber - spectroscopy survey - data reduction

Catheter ablation versus medical therapy for atrial fibrillation with prior stroke history:a prospective propensity score-matched cohort study

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2023年第10期20卷 707-715,I0006页

作者： Wen-li DAI Zi-xu ZHAO Chao jianG liu HE Ke-Xin YAO Yu-feng WANG Ming-Yang GAO Yi-Wei LAI Jing-Rui ZHANG Ming-Xiao li Song ZUO xue-Yuan guo Ri-Bo TANG Song-Nan li Chen-Xi jianG Nian liu De-Yong LONG Xin DU Cai-hua SANG jian-Zeng DONG chang-sheng MA Department of Cardiology Beijing Anzhen HospitalCapital Medical UniversityNational Clinical Research Center for Cardiovascular DiseasesBeijingChina Heart Health Research Center BeijingChina Department of Cardiovascular Medicine the First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina

BACKGROUND Patients with atrial fibrillation(AF)and prior stroke history have a high risk of cardiovascular events despite anticoagulation *** is unclear whether catheter ablation(CA)has further benefits in these *** AF patients with a previous history of stroke or systemic embolism(SE)from the prospective Chinese Atrial Fibrillation Registry study between August 2011 and December 2020 were included in the *** were matched in a 1:1 ratio to CA or medical treatment(MT)based on propensity *** primary outcome was a composite of all-cause death or ischemic stroke(IS)/*** During a total of 4.1±2.3 years of follow-up,the primary outcome occurred in 111 patients in the CA group(3.3 per 100 person-years)and in 229 patients in the MT group(5.7 per 100 person-years).The CA group had a lower risk of the primary outcome compared to the MT group[hazard ratio(HR)=0.59,95%CI:0.47–0.74,Plity(HR=0.43,95%CI:0.31–0.61,Plity(HR=0.32,95%CI:0.19–0.54,Plinical trials are warranted to confirm the benefits of CA in these patients.

关键词： prospective fibrillation matched

Data processing and data products from 2017 to 2019 campaign of astronomical site testing at Ali,Daocheng and Muztagh-ata

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 109-130页

作者： Zi-huang Cao Jin-Xin Hao Lu feng Hugh RAJones jian li Jing xu li-Yong liu Teng-Fei Song jian-feng Wang hua-lin Chen Yan-Jie xue huang Shen Yong-Heng Zhao Zhao-xiang Qi jian-Rong Shi Yuan Tian Zheng Wang Xia Wang Jin-liang Hou Jin-Ming Bai Ji Yang xu Zhou Yong-Qiang Yao Jia Yin Ali Esamdin Guang-Xin Pu Peng Wei Chun-Hai Bai guo-Jie feng Lu Ma xuan Zhang Yu liu Chong Pei Zhi-Xia Shen Yun-Ying jiang jian-feng Tian Xian-Qun Zeng Zhi-Gang Hou xu Yang Jun-Bo Zhang Shi-Long liao Dong-Wei Fan Yun-Fei xu jian-Ping Xiong Tai-sheng Yan Xi Zhang chang-hua li Yi-Han Tao Si-Cheng Yu Zhi-Song Cao Hong-Shuai Wang National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Centre for Astrophysics University of HertfordshireHatfieldUK School of Journalism Communication University of ChinaBeijing 100024China Nanjing Institute of Astronomical Optics&Technology Chinese Academy of SciencesNanjing 210042China Xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China Yunnan Observatories Chinese Academy of SciencesKunming 650216China Purple Mountain Observatory Chinese Academy of SciencesNanjing 210033China Beijing Kaiyang Space Technology Co. LtdBeijing 100085China

Based on previous site testing and satellite cloud data,Ali,Daocheng and Muztagh-ata have been selected as candidate sites for the Large Optical/Infrared Telescope(LOT) in *** present the data collection,processing,management and quality analysis for our site testing based on using similar *** analyze meteorological data,seeing,background light,cloud and precipitable water vapor data from 2017 March 10 to 2019 March *** also investigated the relative usefulness of our all-sky camera data in comparison to that from the meteorological TERRA satellite data based on a night-by-night comparison of the correlation and consistency between *** find a 6% discrepancy arising from a wide range of factors.

关键词： LOT Site-selection-data processing

Long-term analysis of clear nights using satellite data considering astronomical sites in western China

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2020年第6期20卷 96-108页

作者： Zi-huang Cao li-Yong liu Yong-Heng Zhao Lu feng Hugh RAJones huang Shen Jin-Xin Hao Yan-Jie xue Yong-Qiang Yao Jing xu Ali Esamdin Zhao-xiang Qi jian-Rong Shi jian li Yuan Tian Zheng Wang Tai-sheng Yan Xia Wang jian-Ping Xiong Si-Cheng Yu Jun-Bo Zhang Zhi-Xia Shen Yun-Ying jiang Jia Yin Guang-Xin Pu Peng Wei Chun-Hai Bai guo-Jie feng Lu Ma Teng-Fei Song jian-feng Wang jian-feng Tian Xian-Qun Zeng Zhi-Gang Hou Shi-Long liao Zhi-Song Cao Dong-Wei Fan Yun-Fei xu chang-hua li Yi-Han Tao National Astronomical Observatories Chinese Academy of SciencesBeijing 100101China University of Chinese Academy of Sciences Beijing 100049China Shanghai Astronomical Observatory Chinese Academy of SciencesShanghai 200030China Centre for Astrophysics University of HertfordshireHatfieldUK School of Journalism.Communication University of China Beijing 100024China Xinjiang Astronomical Observatory Chinese Academy of SciencesUrumqi 830011China Yunnan Observatories Chinese Academy of SciencesKunming 650216China

A large ground-based optical/infrared telescope is being planned for a world-class astronomical site in *** cloud-free night percentage is the primary meteorological consideration for evaluating candidate *** data from GMS and NOAA satellites and the MODIS instrument were utilized in this research,covering the period from 1996 to *** data analysis benefits from overlapping results from different independent teams as well as a uniform analysis of selected sites using GMS+NOAA *** significant ground-based monitoring is needed to validate these findings,we identify three different geographical regions with a high percentage of cloud-free conditions(~83%on average),which is slightly lower than at Mauna Kea and Cerro Armazones(~85%on average)and were chosen for the large international projects TMT and ELT *** study finds evidence that cloud distributions and the seasonal changes affected by the prevailing westerly winds and summer monsoons reduce the cloud cover in areas influenced by the *** is consistent with the expectations from climate change models and is suggestive that most of the identified sites will have reduced cloud cover in the future.

关键词： methods statistical-site testing-atmospheric effects-MODIS

在线全文

学校读者我要写书评

暂无评论

大断面轴承钢控轧控冷工艺的模拟与分析

东北大学学报（自然科学版） 2006年第6期27卷 658-661页

作者：李胜利徐建忠王国栋刘相华东北大学轧制技术及连轧自动化国家重点实验室辽宁沈阳110004

利用Gleeble 1500热模拟实验机,研究了轴承钢在850℃终轧后,不同冷却速度对其显微组织结构的影响规律.采用ANSYS有限元软件,模拟了大断面轴承钢在不同工艺制度下的温度场分布.结果表明:冷却速度是影响轴承钢碳化物析出的主要因素,在850... 详细信息

利用Gleeble 1500热模拟实验机,研究了轴承钢在850℃终轧后,不同冷却速度对其显微组织结构的影响规律.采用ANSYS有限元软件,模拟了大断面轴承钢在不同工艺制度下的温度场分布.结果表明:冷却速度是影响轴承钢碳化物析出的主要因素,在850℃终轧变形后,为了抑制网状的析出,冷却速度应达到3℃/s左右为宜;轴承钢断面越大,在快速冷却过程中,表面与心部的温度差越大(最大温差约450℃),心部冷却越困难;直径为60 mm以下圆钢,通过冷却强度与冷却制度的合理匹配,可以控制心部的冷速达到3℃/s,从而抑制网状碳化物析出.

关键词：轴承钢碳化物模拟控冷网状碳化物

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma(CHANCE001)

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第3期8卷 1198-1207页

作者： Hai-Dong Zhu Hai-liang li Ming-sheng huang Wei-Zhu Yang guo-Wen Yin Bin-Yan zhong Jun-Hui Sun Zhi-Cheng Jin jian-jian Chen Nai-jian Ge Wen-Bin Ding Wen-Hui li Jin-hua huang Wei Mu Shan-Zhi Gu Jia-Ping li Hui Zhao Shu-Wei Wen Yan-Ming Lei Yu-sheng Song Chun-Wang Yuan Wei-Dong Wang Ming huang Wei Zhao jian-Bing Wu Song Wang xu Zhu jian-Jun Han Wei-Xin Ren Zai-Ming Lu Wen-Ge Xing Yong Fan Hai-Lan lin Zi-Shu Zhang guo-Hui xu Wen-Hao Hu Qiang Tu Hong-Ying Su Chuan-sheng Zheng Yong Chen xu-Ya Zhao Zhu-Ting Fang Qi Wang Jin-Wei Zhao Ai-Bing xu jian xu Qing-hua Wu huan-Zhang Niu jian Wang feng Dai Dui-Ping feng Qing-Dong li Rong-Shu Shi Jia-Rui li Guang Yang Hai-Bin Shi jian-Song Ji Yu-E liu Zheng Cai Po Yang Yang Zhao Xiao-li Zhu li-Gong Lu Gao-Jun Teng Center of Interventional Radiology&Vascular Surgery Department of RadiologyZhongda HospitalMedical SchoolSoutheast UniversityNanjing 210009China Department of Minimally invasive Intervention The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of Interventional Radiology the Third Affiliated HospitalSun Yat-Sen UniversityGuangzhou 510630China Department of Interventional Radiology Union Hospital of Fujian Medical UniversityFuzhou 350001China Department of Interventional Radiology Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical UniversityNanjing 210009China Department of Interventional Radiology The First Affiliated Hospital of Soochow UniversitySoochow UniversitySuzhou 215006China Hepatobiliary and Pancreatic Interventional Treatment Center Division of Hepatobiliary and Pancreatic SurgeryThe First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Interventional Radiology Eastern Hospital of Hepatobiliary SurgeryNavy Medical University(Second Military Medical University)Shanghai 200438China Department of Interventional Radiology Nantong First People’s HospitalNantong 226001China Department of Interventional Radiology Yancheng Third People’s HospitalYancheng 224008China Department of Minimally Invasive Interventional Therapy Sun YatSen University Cancer CenterGuangzhou 510060China Department of Vascular Surgery Southwest HospitalThird Military Medical University(Army Medical University)Chongqing 400038China. Department of Interventional Radiology Hunan Cancer HospitalChangsha 410031China Department of Interventional Oncology The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080China Department of Interventional Radiology The Hospital of Nantong UniversityNantong 226001China Department of Interventional Therapy Shanxi Tumor HospitalTaiyuan 030001China Department of Interventional Radiology Tibet Autonomous Region People’s

There is considerable potential for integrating transarterial chemoembolization(TACE),programmed death-(ligand)1(PD-[L]1)inhibitors,and molecular targeted treatments(MTT)in hepatocellular carcinoma(HCC).It is necessary to investigate the therapeutic efficacy and safety of TACE combined with PD-(L)1 inhibitors and MTT in real-world *** this nationwide,retrospective,cohort study,826 HCC patients receiving either TACE plus PD-(L)1 blockades and MTT(combination group,n=376)or TACE monotherapy(monotherapy group,n=450)were included from January 2018 to May *** primary endpoint was progression-free survival(PFS)according to modified *** secondary outcomes included overall survival(OS),objective response rate(ORR),and *** performed propensity score matching approaches to reduce bias between two *** matching,228 pairs were included with a predominantly advanced disease *** PFS in combination group was 9.5 months(95%confidence interval[CI],8.4-11.0)versus 8.0 months(95%CI,6.6-9.5)(adjusted hazard ratio[HR],0.70,P=0.002).OS and ORR were also significantly higher in combination group(median OS,19.2[16.1-27.3]vs.15.7 months[13.0-20.2];adjusted HR,0.63,P=0.001;ORR,60.1%vs.32.0%;P<0.001).Grade 3/4 adverse events were observed at a rate of 15.8%and 7.5%in combination and monotherapy groups,*** results suggest that TACE plus PD-(L)1 blockades and MTT could significantly improve PFS,OS,and ORR versus TACE monotherapy for Chinese patients with predominantly advanced HCC in real-world practice,with an acceptable safety profile.

关键词： hepatocellular targeted matching

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin ling Qiao-Nan Shan xu-Yong Wei Rui Wang chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan xu Lai-Bang Luo li-Bo Sun Guang-Ming li Tai-Shi Fang Nan jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng Ren Lang Tao jiang Qiang He lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi guo liu-Gen Lan xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian jian-hua Shi Bo Wang jiang liu Qian Lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang lin zhong Jing-sheng Ma Qi-Gen li sheng-Dong Wu chang-jiang Lu Cai-De Lu Dong-hua Zhang xuan Wang Zi-Qiang li Mu-jian Teng Jun-Jie li Wen-Tao jiang jian-hua li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-hua Song Zhi-Ren Fu Wei Qiu guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang jian Zhou Gang Chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong guo Shu-Sen Zheng Xiao xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion